abstract |
The invention is related to suitably modified antisense oligonucleotide (ODN) sequences against Smad7, and their uses in the medical field as therapeutic biological agents, in particular in the treatment of gastrointestinal inflammatory diseases, such as Crohn's disease and ulcerative colitis. |